Bond.az White LogoBond.az Black Logo

Bill.com price target cut to $45 on take rate outlook

Truist Securities cuts Bill.com price target to $45 from $46, maintains Buy rating. Updated model reflects slower take rate expansion and cost-cutting measures.

Sebastian Young
BySebastian Young- Senior Editor
|
0

Truist Securities lowered its price target on Bill.com Holdings Inc. (NYSE:BILL) to $45 from $46 while maintaining a Buy rating on the stock.

The firm updated its financial model following Bill.com's third-quarter fiscal 2026 earnings report. Core revenue forecasts decreased slightly by less than 1% due to a slower pace of take rate expansion for the accounts payable and accounts receivable business.

Truist raised its fiscal 2027 adjusted operating income forecast by 23% and its fiscal 2027 adjusted earnings per share forecast by 27%. The increases reflect the company's 30% reduction in force and new $1 billion buyback authorization.

The firm noted that Bill.com management will provide a roadmap to reaching the Rule of 40 on next quarter's call. Street estimates currently stand at a Rule of 37 in fiscal 2028.

The new price target is based on approximately 16.0 times Truist's definition of calendar year 2027 adjusted earnings per share, which incorporates stock-based compensation as an expense.

More News
Today / 15:23
|
844

Legence Price Target Raised on AI Data Center Demand

Tigress Financial raises Legence price target to $125 on AI data center demand, citing record backlog and growth acceleration.

0
Today / 15:01
|
898

Truist Raises Acushnet Target to $97

Truist Securities boosts Acushnet price target to $97, citing healthy trends. Hold rating maintained. Read more on Bond.az.

0
Today / 14:53
|
873

Piper Sandler Reiterates Boston Scientific Buy Rating

Piper Sandler reiterated an Overweight rating on Boston Scientific. Agent DCB drives growth; stock undervalued per Bond.az.

0
Today / 14:52
|
436

Piper Sandler Reiterates Overweight on Climb Bio

Piper Sandler reiterates Overweight on Climb Bio. IgAN opportunity and CLYM116 outlook.

0
Today / 14:51
|
546

Piper Sandler cuts e.l.f. Beauty target to $60

Piper Sandler cuts e.l.f. Beauty price target to $60 from $85, maintains Neutral rating. Stock trades at $53.23 near 52-week low.

0
Today / 12:32
|
795

Morgan Stanley Reiterates Home Depot Rating on Execution

Morgan Stanley reiterates Overweight rating on Home Depot with $420 target, citing solid execution in a growthless housing market.

0
Today / 12:31
|
212

Compass Point Lowers DeFi Tech Target

Compass Point cuts DeFi Technologies price target to $1.45, maintains Buy rating amid bear market.

0
Today / 12:30
|
656

Benchmark Reiterates Baidu Stock Rating on AI Revenue Milestone

Benchmark reaffirms Buy rating on Baidu after AI revenue milestone. AI Cloud margins improve, new products launched.

0
Today / 12:04
|
952

Raymond James Backs Nutrien Stock on Potash

Raymond James backs Nutrien stock with Outperform rating and $90 target after Indian potash deal. 26% upside, strong financials.

0
Today / 11:35
|
858

Mizuho Raises STM Price Target on AI Growth

Mizuho raises STMicroelectronics price target to $68, citing AI growth and new technologies.

0
Today / 11:03
|
967

Oppenheimer Reiterates Outperform on UroGen Pharma

Oppenheimer reiterates Outperform on UroGen Pharma with $40 target. Strong commercial momentum for Zusduri driven by physician enthusiasm.

0
Today / 11:02
|
510

Guggenheim Upgrades StubHub Stock on Reset

Guggenheim upgrades StubHub stock to Buy with a $12.50 price target, citing reset expectations and growth catalysts like the World Cup.

0
...